Types
- By where it starts: invasive ductal carcinoma (no special type), the most common; invasive lobular carcinoma; and ductal carcinoma in situ (DCIS), a non-invasive early form1.
- By biology, which drives treatment1:
- Hormone receptor–positive, HER2-negative — the most common
- HER2-positive
- Triple-negative — no estrogen, progesterone, or HER2 receptors
- Inflammatory breast cancer and breast cancer in men are rare forms.
Prevention
- The USPSTF recommends a screening mammogram every 2 years for women ages 40 to 74. Screening finds cancer earlier rather than preventing it2.
- Women at high risk can lower their risk with medication, and carriers of high-risk gene variants may choose risk-reducing surgery1.
Risk factors
- Female sex and older age1
- Inherited variants in BRCA1, BRCA2, PALB2, and other genes3
- Family history of breast or ovarian cancer1
- Alcohol — risk rises even at 3 to 6 drinks a week5
- Longer lifetime estrogen exposure: early first period, late menopause, first pregnancy after 30 or none, combined menopausal hormone therapy1
- Dense breast tissue, chest radiation at a young age, and weight gain after menopause1
Diagnostics
- Screening mammography every 2 years from age 40 to 742.
- Diagnostic imaging — diagnostic mammogram and ultrasound for a lump or abnormal screen; MRI for some high-risk women and for planning surgery1.
- Biopsy, usually with a core needle, confirms cancer and provides tissue for biomarker tests1.
- Staging combines tumor size, lymph nodes, and spread with the tumor's biomarkers1.
Treatments
- Surgery — breast-conserving surgery (lumpectomy) or mastectomy, with sentinel lymph-node biopsy1.
- Radiation therapy after breast-conserving surgery, and after mastectomy in some cases1.
- Endocrine (hormone) therapy for hormone receptor–positive cancer, usually for 5 years or more1.
- HER2-targeted therapy for HER2-positive cancer1.
- Chemotherapy, before or after surgery. For many early hormone receptor–positive cancers, a 21-gene test shows who can safely skip it4.
- Immunotherapy with chemotherapy for some triple-negative cancers1.
Molecular Biomarkers
- Estrogen and progesterone receptors (ER, PR) — predict benefit from endocrine therapy1.
- HER2 — overexpression or gene amplification predicts benefit from HER2-targeted drugs1.
- Ki-67 — shows how quickly cancer cells are dividing1.
- 21-gene recurrence score — in the TAILORx trial, women with hormone receptor–positive, HER2-negative, node-negative cancer and a mid-range score (11–25) did as well with endocrine therapy alone as with added chemotherapy, though women 50 or younger with scores of 16–25 gained some benefit from chemotherapy4.
- In advanced cancer, tumors are tested for changes such as PIK3CA and ESR1 mutations that make targeted drugs an option.
Genes
- A study of more than 113,000 women confirmed that damaging variants in ATM, BRCA1, BRCA2, CHEK2, and PALB2 raise breast cancer risk, and implicated BARD1, RAD51C, RAD51D, and TP53 as well3.
- Carriers of high-risk variants may be offered earlier and more intensive screening, preventive medication, or risk-reducing surgery1.
Lifestyle
- Drink less alcohol, or none5.
- Stay physically active and avoid weight gain after menopause1.
- Breastfeeding is linked to lower risk1.
- Discuss the risks and benefits of menopausal hormone therapy with your clinician1.
Nutrition
- No single food prevents breast cancer. Alcohol is the clearest dietary risk5.
- Eating in a way that helps you keep a healthy weight after menopause lowers risk1.
Medical Interventions
- Breast-conserving surgery, mastectomy, and breast reconstruction1
- Radiation therapy1
- Risk-reducing mastectomy and removal of the ovaries for high-risk gene carriers1
Pharmaceutical Drugs
- Endocrine therapy: tamoxifen; aromatase inhibitors anastrozole, letrozole, and exemestane; ovarian suppression before menopause1
- HER2-targeted drugs: trastuzumab, pertuzumab, trastuzumab emtansine, trastuzumab deruxtecan1
- CDK4/6 inhibitors: palbociclib, ribociclib, abemaciclib1
- PARP inhibitors: olaparib and talazoparib for BRCA carriers1
- Immunotherapy: pembrolizumab for some triple-negative cancers1
- Risk reduction: tamoxifen, raloxifene, anastrozole, or exemestane for women at high risk1
Sources
- Loibl S, Poortmans P, Morrow M, Denkert C, Curigliano G. Breast cancer. Lancet. 2021;397(10286):1750-1769. doi:10.1016/S0140-6736(20)32381-3
- US Preventive Services Task Force; Nicholson WK, Silverstein M, et al. Screening for breast cancer: US Preventive Services Task Force recommendation statement. JAMA. 2024;331(22):1918-1930. doi:10.1001/jama.2024.5534
- Breast Cancer Association Consortium. Breast cancer risk genes — association analysis in more than 113,000 women. N Engl J Med. 2021;384(5):428-439. doi:10.1056/NEJMoa1913948
- Sparano JA, Gray RJ, Makower DF, et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med. 2018;379(2):111-121. doi:10.1056/NEJMoa1804710
- Chen WY, Rosner B, Hankinson SE, Colditz GA, Willett WC. Moderate alcohol consumption during adult life, drinking patterns, and breast cancer risk. JAMA. 2011;306(17):1884-1890. doi:10.1001/jama.2011.1590
This page summarizes published research for education. It isn't medical advice and doesn't replace care from a clinician who knows your history. Never start, stop, or change a medication without talking to your prescriber.